Treatment of Radical Resected NSCLC by Chinese Medicine Combined with Adjuvant Chemother- apy: a Clinical Study.
- Author:
Wan-xin HOU
;
He-gen LI
;
Zhi-wei CHEN
;
Li-hua ZHU
;
Li-hong ZHAO
;
Jian-hui TIAN
;
Wei-jie XU
;
Lei ZHOU
;
Yi-lin YAO
- Publication Type:Journal Article
- MeSH: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; therapeutic use; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Carboplatin; therapeutic use; Carcinoma, Non-Small-Cell Lung; drug therapy; Chemotherapy, Adjuvant; Cisplatin; therapeutic use; Cohort Studies; Disease-Free Survival; Drugs, Chinese Herbal; therapeutic use; Humans; Lung Neoplasms; Quality of Life; Vinblastine; analogs & derivatives; therapeutic use
- From: Chinese Journal of Integrated Traditional and Western Medicine 2015;35(6):648-653
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy of Chinese medicine (CM) combined adjuvant chemotherapy in postponing relapse and metastasis of radical resected Ib-IIIa stage non-small cell lung cancer (NSCLC) patients, and to explore its effect in improving their quality of life (QOL) and clinical symptoms.
METHODSWe designed a cohort study of 336 radical resected Ib-IIIa NSCLC patients by analyzing disease free survival (DFS) using Log-rank test. They were randomly assigned to the control group (155 cases, treated by adjuvant chemotherapy group) and the test group (181 cases, treated by adjuvant chemotherapy combined CM). By using controlled method, 60 radical resected NSCLC patients undergoing NP/NC program in 2012 (vinorelbine 25 mg/m2, combined with cisplatin 75 mg/m2 on day 1 and day 8/on day 1 or on day 1, 2, and 3; or carboplatin AUC = 5 on day 1) were assigned to the control group (29 cases) and the test group (31 cases). QOL scores (using EORTC QLQ-LC43 questionnaire) and TCM symptoms scores were compared between the two groups before chemotherapy, peri-chemotherapy (one day before the 2nd course of chemotherapy) , and after chemotherapy (20 days after ending the 4th course of chemotherapy).
RESULTS(1) The median DFS was longer in the test group than in the control group, but with no statistical difference between the two groups (42.73 months vs 35.57 months , P = 0.179). In the subgroup analysis, there was statistical difference in IIIa stage DFS. The median IIIa stage DFS of was longer in the test group than in the control group with statistical difference (27.87 months vs 19. 93 months, P = 0.047). (2) In the control study, repeated measured data indicated there was significant difference in physical functions between the two groups (P < 0.05). Total scores for health states decreased more in the test group than in the control group, but with no statistical difference (P > 0.05). Scores for constipation and CM syndrome scores were higher in the test group than in the control group (P < 0.05).
CONCLUSIONSCM had advantages in postponing DFS of radical resected NSCLC patients, especially in IIIa stage. CM could improve their QOL and clinical symptoms during adjuvant chemotherapy.